Register Login
Register to leave comments
  • News bot Oct. 2, 2025, 5:54 p.m.

    📋 ADAPTIMMUNE THERAPEUTICS PLC (ADAP) - Financial Results

    Filing Date: 2022-08-04

    Accepted: 2022-08-04 07:36:18

    Event Type: Financial Results

    Event Details:

    Adaptimmune Therapeutics plc (ADAP) Reports Q3 2022 Financial Results Adaptimmune Therapeutics plc (ADAP) announced its financial results for the period ending Q3 2022. Key Financial Highlights:
    • Revenue: (6,758)
    • Net Income: Not disclosed
    • EPS: Not disclosed
    • Cash and equivalents: 99524
      • targeting MAGE-A4 ​Financial Results for the three and six months ended June 30, 2022
      • planned for 2023
      • targeting MAGE-A4, afami-cel, to achieve meaningful clinical responses beyond sarcoma●ADP-A2M4CD8 is being investigated in the SURPASS family of trials●Last year, at the European Society for Medical Oncology (ESMO) 2021

    📊 Key Financial Metrics (Year-over-Year Comparison):

    Metric 2022 2021 Change ($) Change (%)
    Revenue 3.10K 9.11K $-6.02K -66.04%
    Operating Expenses Interest Income 266.00 695.00 $-429.00 -61.73%
    Operating Expenses Total Other Income Expense 54.00 -643.00 $697.00 +108.40%
    Current Liabilities Accounts Payable 15.99K 15.99K $0.00 +0.00%
    Cash Flows From Operating Activities Net Loss -94.78K -94.78K $0.00 +0.00%
    Revenue 5.54K 5.54K $0.00 +0.00%
    Interest Income 357.00 357.00 $0.00 +0.00%
    Net Loss -44.52K -44.52K $0.00 +0.00%
    Intangible Assets, Net 612.00 612.00 $0.00 +0.00%
    Accounts Payable 15.99K 15.99K $0.00 +0.00%
    Operating Lease Liabilities 2.56K 2.56K $0.00 +0.00%

    💼 Business Developments:

    • Partnership
    • Acquisition
    • Licensing
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: Adaptimmune Therapeutics plc
    • CIK: 0001621227
    • Ticker Symbol: ADAP
    • Period End Date: 2022-08-04
    • Document Type: 8-K

Search

News categories